Biotechnology Value Fund, L.P. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who started this subject	11/1/2000 9:44:54 AM
From: nigel bates	Read Replies (1) of 4974

Nov. 1 /PRNewswire/ -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP - news) announced today the pricing of a public offering of 5.35 million shares of common stock at a price of $70 per share with gross proceeds totaling $374.5 million. The Company has granted the underwriters an option to purchase up to 802,500 additional shares to cover over-allotments, if any. The underwriting group consists of Robertson Stephens, Inc. and Lehman Brothers Inc., as joint book-running managers, Prudential Vector Healthcare Group, a unit of Prudential Securities, Lazard Freres & Co. LLC and Adams, Harkness & Hill, Inc....

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next